Social factors, blood markers and mood symptoms in brain diseases and mental disorders
Studies how social factors and blood markers relate to psychiatric symptoms in adults.
Plain-language title generated from the registry record
Registry title: Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a mental disorder or a neurodegenerative disease, and also unaffected volunteers as controls. Everyone gives a blood sample and has a full clinical and psychological assessment.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Patients with a mental disorder or a neurodegenerative disease (depression, schizophrenia, bipolar 1 disorder, Alzheimer disease, Parkinson disease, frontotemporal dementia, dementia with Lewy bodies). Controls have no such diagnosis.
- Earlier treatment
- People cannot have had potentially neurotoxic chemotherapy or cranial radiotherapy. People cannot be on anticoagulant treatment.
- Biomarker or test result
- Alzheimer's disease must fit the blood or spinal fluid markers. Healthy controls must not show Alzheimer's or other neurodegenerative markers.
Main reasons for not taking part
- No neuropsychological data
- Anticoagulant treatment, such as warfarin or apixaban
- Drug abuse in the last year
- Cancer affecting the central nervous system, unless in complete remission for 5 years or longer
- Potentially neurotoxic chemotherapy or cranial radiotherapy
Read by machine on 9 November 2026.
Where in Spain
- IRSPBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07239843
- Record updated
- 24 April 2026
- Original description
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for psychiatric symptoms with biological changes in patients suffering from a mental disorder (MD) or a neurodegenerative disease (ND).Read full original descriptionShow less
Synapsing's Multinational Sociodemographic Study
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for psychiatric symptoms with biological changes in patients suffering from a mental disorder (MD) or a neurodegenerative disease (ND).
Inclusion: Age>18 and donation of blood,; full clinical and psychological assessment; Available neuroimaging is optional as not all patients are suitable; Age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls; Unaffected controls are usually spouses or children of patients that are informed about our studies at each clinical site.
Exclusion: anticoagulant treatment such as acenocoumarol, heparin, warfarin, dabigatran, rivaroxaban, apixaban, drug abuse in the last year,; the patient has received potentially neurotoxic chemotherapy and/or patient has received cranial radiotherapy; medical history of cancer affecting the central nervous system that has not been in complete remission for 5 years or longer,; Clinical diagnosis of Alzheimer's disease where pathophysiological markers (measured in CSF or plasma) are inconsistent with Alzheimer's disease pathophysiology; Cognitively healthy volunteers where pathophysiological markers (measured in CSF or plasma) are consistent with Alzheimer's disease or other neurodegenerative pathophysiology; Lack of neuropsychological data,.